December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
Webcast

November 04, 2009
Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

September 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference

August 5, 2009
Flamel Technologies Announces Second Quarter 2009 Results

July 28, 2009
Flamel Technologies Announces Projected Release Date of Second Quarter Results; Conference Call

July 13, 2009
Baxter and Flamel Technologies Announce Program to Formulate Longer Acting Forms of Blood Clotting Factors

June 25, 2009
Flamel Technologies Announces Two New Feasibility Agreements

June 24, 2009
Flamel Technologies Announces Results of Annual Meeting

June 22, 2009
Flamel Technologies Announces New Feasibility Projects; Technology Access Fee

May 11, 2009
Flamel Technologies Announces Profitable First Quarter Results; Increased Cash Levels

May 05, 2009
Flamel Technologies Announces Projected Release Date of First Quarter Results; Conference Call

March 20, 2009
Flamel Technologies to Receive $4 Million Milestone Payment from GlaxoSmithKline

March 16, 2009
Flamel Technologies to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
Webcast

March 4, 2009
Flamel Technologies Announces Fourth Quarter and Year-End 2008 Results;
Fourth quarter highlights include further diversification through new Medusa and Micropump partnered agreements; significantly improved financial performance

February 24, 2009
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

February 23, 2009
Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer

February 17, 2009
Flamel Technologies Announces Merck Serono's Exercise of Option to License Medusa Technology of Development of an Extended-Release Formulation of a Therapeutic Protein